Dr Lalchandani Labs Ltd
Incorporated in 2011, Dr. Lalchandani Labs Ltd is in the business of running laboratories
for pathological investigations[1]
- Market Cap ₹ 7.80 Cr.
- Current Price ₹ 18.0
- High / Low ₹ 28.7 / 9.80
- Stock P/E 16.6
- Book Value ₹ 23.4
- Dividend Yield 0.00 %
- ROCE 2.81 %
- ROE 3.08 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.77 times its book value
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -26.0%
- The company has delivered a poor sales growth of -6.11% over past five years.
- Promoter holding is low: 31.2%
- Company has a low return on equity of -7.04% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.0.29 Cr.
- Company has high debtors of 431 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Half Yearly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| 2.79 | 5.26 | 6.10 | 9.78 | 11.28 | 5.04 | 4.81 | 4.45 | 4.38 | |
| 2.17 | 4.06 | 4.84 | 7.54 | 8.81 | 4.95 | 4.59 | 3.52 | 3.61 | |
| Operating Profit | 0.62 | 1.20 | 1.26 | 2.24 | 2.47 | 0.09 | 0.22 | 0.93 | 0.77 |
| OPM % | 22.22% | 22.81% | 20.66% | 22.90% | 21.90% | 1.79% | 4.57% | 20.90% | 17.58% |
| 0.03 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | 1.40 | 0.13 | 0.29 | |
| Interest | 0.16 | 0.14 | 0.18 | 0.35 | 0.60 | 0.99 | 0.38 | 0.09 | 0.04 |
| Depreciation | 0.13 | 0.35 | 0.42 | 0.52 | 0.59 | 0.66 | 0.62 | 0.56 | 0.56 |
| Profit before tax | 0.36 | 0.72 | 0.66 | 1.37 | 1.28 | -1.56 | 0.62 | 0.41 | 0.46 |
| Tax % | 25.00% | 26.39% | 28.79% | 26.28% | 28.12% | -0.00% | -0.00% | -2.44% | |
| 0.26 | 0.53 | 0.47 | 1.01 | 0.93 | -1.56 | 0.62 | 0.42 | 0.47 | |
| EPS in Rs | 0.89 | 1.22 | 1.08 | 2.33 | 2.15 | -3.60 | 1.43 | 0.97 | 1.08 |
| Dividend Payout % | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% | -0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -27% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -9% |
| 3 Years: | -31% |
| TTM: | -45% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -13% |
| 1 Year: | 11% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | -7% |
| Last Year: | 3% |
Balance Sheet
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 2.93 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 | 4.33 |
| Reserves | 0.40 | 3.73 | 4.21 | 5.22 | 6.15 | 4.59 | 5.21 | 5.62 | 5.82 |
| 1.88 | 0.90 | 1.76 | 4.04 | 5.15 | 6.40 | 3.48 | 4.07 | 4.58 | |
| 1.00 | 1.18 | 1.63 | 1.61 | 2.49 | 2.40 | 1.97 | 1.72 | 1.36 | |
| Total Liabilities | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
| 2.06 | 3.28 | 3.47 | 5.24 | 5.75 | 5.39 | 3.99 | 3.51 | 3.38 | |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.24 | 0.41 | 0.27 | 0.27 |
| 3.91 | 6.62 | 8.22 | 9.72 | 12.13 | 12.09 | 10.59 | 11.96 | 12.44 | |
| Total Assets | 6.21 | 10.14 | 11.93 | 15.20 | 18.12 | 17.72 | 14.99 | 15.74 | 16.09 |
Cash Flows
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| 0.58 | -0.45 | -0.10 | 1.19 | 2.01 | -0.00 | -0.22 | 0.37 | |
| -1.29 | -1.95 | -0.53 | -2.26 | -1.53 | -0.20 | 1.00 | 0.06 | |
| 1.57 | 3.51 | 0.85 | 1.71 | 0.16 | -0.23 | -1.59 | 0.58 | |
| Net Cash Flow | 0.85 | 1.12 | 0.23 | 0.64 | 0.64 | -0.43 | -0.81 | 1.01 |
Ratios
Figures in Rs. Crores
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|
| Debtor Days | 149.14 | 126.99 | 199.25 | 148.54 | 136.55 | 359.93 | 356.65 | 431.44 |
| Inventory Days | 167.03 | 233.36 | 158.70 | 68.75 | 191.07 | 458.51 | 255.15 | 490.47 |
| Days Payable | 426.86 | 406.89 | 355.48 | 97.06 | 175.15 | 404.21 | 217.94 | 365.00 |
| Cash Conversion Cycle | -110.69 | -46.54 | 2.47 | 120.23 | 152.47 | 414.23 | 393.86 | 556.91 |
| Working Capital Days | 162.22 | 167.23 | 206.43 | 104.50 | 77.98 | 188.29 | 163.91 | 156.66 |
| ROCE % | 12.14% | 8.72% | 14.40% | 12.87% | -3.68% | -2.68% | 2.81% |
Documents
Announcements
-
Board Meeting Outcome for Outcome Of Board Meeting
9 Dec - Board meeting on Dec 9 deferred; rights issue/fundraising proposal pending procedural completion.
-
Board Meeting Intimation for Considering Of Raising Of Funds Through A Rights Issue And/Or Any Other Permissible Mode
2 Dec - Board meeting Dec 09, 2025 to consider equity/rights fundraising proposal.
-
Board Meeting Outcome for Unaudited Financial Results For The Half Year Ended September 2025
14 Nov - Qualified review for H1 ended 30 Sep 2025: omitted interest, unprovided gratuity, irregular ESI/EPF/TDS deposits.
- Unaudited Financials Results For The Half Year Ended September 30, 2025 14 Nov
-
Board Meeting Intimation for Consider And Approve Financial Statements For The Half Year Ended 30.09.2025
10 Nov - Board meeting on Nov 14, 2025 to approve unaudited results for half-year ended Sep 30, 2025.
Business Overview:[1][2][3]
DLLL is a NABL accredited company with 5 Self-sufficient Labs and 15 collection centers across Delhi/NCR. It is empaneled for CGHS (South, North and East Block), DJB, MCD, DDA etc. and provides diagnostic and related healthcare tests and services. Company owns, runs laboratories for carrying out pathological investigations of various branches of Bio-Chemistry, Hematology, Histopathology, Microbiology, Electrophoresis, Virology, Cytology, other pathological Investigations and Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA & Genetic Testing etc.